These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 21078951)

  • 21. A phase I/IIa study with succinylated human serum albumin (Suc-HSA), a candidate HIV-1 fusion inhibitor.
    Vermeulen JN; Meijer DK; Over J; Lange J; Proost JH; Bakker HI; Beljaars L; Wit FW; Prins JM
    Antivir Ther; 2007; 12(2):273-8. PubMed ID: 17503670
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug candidate that demonstrates antiviral activity in HIV-1-infected subjects.
    Wang T; Yin Z; Zhang Z; Bender JA; Yang Z; Johnson G; Yang Z; Zadjura LM; D'Arienzo CJ; DiGiugno Parker D; Gesenberg C; Yamanaka GA; Gong YF; Ho HT; Fang H; Zhou N; McAuliffe BV; Eggers BJ; Fan L; Nowicka-Sans B; Dicker IB; Gao Q; Colonno RJ; Lin PF; Meanwell NA; Kadow JF
    J Med Chem; 2009 Dec; 52(23):7778-87. PubMed ID: 19769332
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vicriviroc in combination therapy with an optimized regimen for treatment-experienced subjects: 48-week results of the VICTOR-E1 phase 2 trial.
    Suleiman J; Zingman BS; Diaz RS; Madruga JV; DeJesus E; Slim J; Mak C; Lee E; McCarthy MC; Dunkle LM; Walmsley S
    J Infect Dis; 2010 Feb; 201(4):590-9. PubMed ID: 20064072
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals.
    Markowitz M; Morales-Ramirez JO; Nguyen BY; Kovacs CM; Steigbigel RT; Cooper DA; Liporace R; Schwartz R; Isaacs R; Gilde LR; Wenning L; Zhao J; Teppler H
    J Acquir Immune Defic Syndr; 2006 Dec; 43(5):509-15. PubMed ID: 17133211
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection.
    Elion R; Kaul S; Knupp C; Adler M; Cross AP; Dunkle LM; Kelleher T
    Clin Ther; 1999 Nov; 21(11):1853-63. PubMed ID: 10890257
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1.
    Emu B; Fessel J; Schrader S; Kumar P; Richmond G; Win S; Weinheimer S; Marsolais C; Lewis S
    N Engl J Med; 2018 Aug; 379(7):645-654. PubMed ID: 30110589
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized, placebo controlled, double masked phase IB study evaluating the safety and antiviral activity of aprepitant, a neurokinin-1 receptor antagonist in HIV-1 infected adults.
    Tebas P; Tuluc F; Barrett JS; Wagner W; Kim D; Zhao H; Gonin R; Korelitz J; Douglas SD
    PLoS One; 2011; 6(9):e24180. PubMed ID: 21931661
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety, Pharmacokinetics, and Antiviral Activity of a Novel HIV Antiviral, ABX464, in Treatment-Naive HIV-Infected Subjects in a Phase 2 Randomized, Controlled Study.
    Steens JM; Scherrer D; Gineste P; Barrett PN; Khuanchai S; Winai R; Ruxrungtham K; Tazi J; Murphy R; Ehrlich H
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28507108
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1-Infected Adults.
    Gallant JE; Thompson M; DeJesus E; Voskuhl GW; Wei X; Zhang H; White K; Cheng A; Quirk E; Martin H
    J Acquir Immune Defic Syndr; 2017 May; 75(1):61-66. PubMed ID: 28196003
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection.
    Smith PF; Ogundele A; Forrest A; Wilton J; Salzwedel K; Doto J; Allaway GP; Martin DE
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3574-81. PubMed ID: 17638699
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial.
    Deeks SG; Collier A; Lalezari J; Pavia A; Rodrigue D; Drew WL; Toole J; Jaffe HS; Mulato AS; Lamy PD; Li W; Cherrington JM; Hellmann N; Kahn J
    J Infect Dis; 1997 Dec; 176(6):1517-23. PubMed ID: 9395363
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiviral activity of low-dose alovudine in antiretroviral-experienced patients: results from a 4-week randomized, double-blind, placebo-controlled dose-ranging trial.
    Ghosn J; Quinson AM; Sabo N; Cotte L; Piketty C; Dorléacq N; Bravo ML; Mayers D; Harmenberg J; Mårdh G; Valdez H; Katlama C
    HIV Med; 2007 Apr; 8(3):142-7. PubMed ID: 17461857
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results.
    Murphy RL; Brun S; Hicks C; Eron JJ; Gulick R; King M; White AC; Benson C; Thompson M; Kessler HA; Hammer S; Bertz R; Hsu A; Japour A; Sun E
    AIDS; 2001 Jan; 15(1):F1-9. PubMed ID: 11192874
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients.
    Schapiro JM; Winters MA; Stewart F; Efron B; Norris J; Kozal MJ; Merigan TC
    Ann Intern Med; 1996 Jun; 124(12):1039-50. PubMed ID: 8633817
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542.
    Jacobson JM; Israel RJ; Lowy I; Ostrow NA; Vassilatos LS; Barish M; Tran DN; Sullivan BM; Ketas TJ; O'Neill TJ; Nagashima KA; Huang W; Petropoulos CJ; Moore JP; Maddon PJ; Olson WC
    Antimicrob Agents Chemother; 2004 Feb; 48(2):423-9. PubMed ID: 14742190
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults.
    Lalezari JP; DeJesus E; Northfelt DW; Richmond G; Wolfe P; Haubrich R; Henry D; Powderly W; Becker S; Thompson M; Valentine F; Wright D; Carlson M; Riddler S; Haas FF; DeMasi R; Sista PR; Salgo M; Delehanty J
    Antivir Ther; 2003 Aug; 8(4):279-87. PubMed ID: 14518696
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I/II trial of the anti-HIV activity of mifepristone in HIV-infected subjects ACTG 5200.
    Para MF; Schouten J; Rosenkranz SL; Yu S; Weiner D; Tebas P; White CJ; Reeds D; Lertora J; Patterson KB; Daar ES; Cavert W; Brizz B;
    J Acquir Immune Defic Syndr; 2010 Apr; 53(4):491-5. PubMed ID: 20130470
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects.
    Gruzdev B; Rakhmanova A; Doubovskaya E; Yakovlev A; Peeters M; Rinehart A; de Dier K; Baede-Van Dijk P; Parys W; van 't Klooster G
    AIDS; 2003 Nov; 17(17):2487-94. PubMed ID: 14600520
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proof of activity with AMD11070, an orally bioavailable inhibitor of CXCR4-tropic HIV type 1.
    Moyle G; DeJesus E; Boffito M; Wong RS; Gibney C; Badel K; MacFarland R; Calandra G; Bridger G; Becker S;
    Clin Infect Dis; 2009 Mar; 48(6):798-805. PubMed ID: 19193109
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Maraviroc for previously treated patients with R5 HIV-1 infection.
    Gulick RM; Lalezari J; Goodrich J; Clumeck N; DeJesus E; Horban A; Nadler J; Clotet B; Karlsson A; Wohlfeiler M; Montana JB; McHale M; Sullivan J; Ridgway C; Felstead S; Dunne MW; van der Ryst E; Mayer H;
    N Engl J Med; 2008 Oct; 359(14):1429-41. PubMed ID: 18832244
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.